Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma

被引：0
作者：
Beinfeld, Molly [1 ]
Lee, Sei [2 ]
McQueen, Brett [3 ]
Fluetsch, Noemi [1 ]
Pearson, Steven [1 ]
Ollendorf, Daniel A. [4 ]
机构：
[1] Inst Clin & Econ Review, Boston, MA 02109 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80309 USA
[4] Tufts Med Ctr, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2020年 / 27卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：1315 / 1320
页数：6
相关论文
共 50 条
  • [31] Clinical updates of B-cell maturation antigen-targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review)
    Xing, Rui
    Wang, Meidan
    Wang, Liqun
    Pan, Mingyue
    Wang, Yixi
    Zhou, Hongwei
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2025, 55 (02)
  • [32] Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma
    Salem, Dalia A.
    Maric, Irina
    Yuan, Constance M.
    Liewehr, David J.
    Venzon, David J.
    Kochenderfer, James
    Stetler-Stevenson, Maryalice
    LEUKEMIA RESEARCH, 2018, 71 : 106 - 111
  • [33] Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma
    Huang, He
    uW, Heng-wei
    Hu, Yong-xian
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2020, 21 (01): : 29 - 41
  • [34] Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
    Lee, Lydia
    Bounds, Danton
    Paterson, Jennifer
    Herledan, Gaelle
    Sully, Katherine
    Seestaller-Wehr, Laura M.
    Fieles, William E.
    Tunstead, James
    McCahon, Lee
    Germaschewski, Fiona M.
    Mayes, Patrick A.
    Craigen, Jenny L.
    Rodriguez-Justo, Manuel
    Yong, Kwee L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (06) : 911 - 922
  • [35] Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
    Davis, James A.
    Dima, Danai
    Ahmed, Nausheen
    DeJarnette, Shaun
    McGuirk, Joseph P.
    Khouri, Jack
    Valent, Jason
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [36] Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
    Kambhampati, Swetha
    Sheng, Ying
    Huang, Chiung-Yu
    Bylsma, Sophia
    Lo, Mimi
    Kennedy, Vanessa
    Natsuhara, Kelsey
    Martin, Thomas
    Wolf, Jeffrey
    Shah, Nina
    Wong, Sandy W.
    BLOOD ADVANCES, 2022, 6 (07) : 2045 - 2054
  • [37] Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
    Theprungsirikul, Poy
    Yu, Mansen
    Liu, Yuxin
    Rall, Kerri
    Matthews, Martin
    Neparidze, Natalia
    Parker, Terri
    Browning, Sabrina
    Anderson, Tara
    Stevens, Erica
    Foss, Francine
    Gowda, Lohith
    Pillai, Manoj
    Isufi, Iris
    Seropian, Stuart
    Mirza, Sayeef
    Bar, Noffar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S92 - S93
  • [38] Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)
    Jagannath, Sundar
    Berdeja, Jesus G.
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam
    Madduri, Deepu
    Hari, Parameswaran
    Yeh, Tzu-Min
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn C.
    Allred, Alicia
    Zudaire, Enrique
    Deraedt, William
    Wu, Xiaoling
    Pacaud, Lida
    Akram, Muhammad
    Lin, Yi
    Martin, Thomas
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S15 - S16
  • [39] CAR plus T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma
    Harrison, Simon J.
    Nguyen, Tamia
    Rahman, Marzia
    Er, Jeremy
    Li, Jessica
    Li, Katherine
    Lendvai, Nikoletta
    Schecter, Jordan M.
    Banerjee, Arnob
    Roccia, Tito
    Foulk, Brad
    Gu, Junchen
    Zhao, Hao
    Smirnov, Denis
    Slaughter, Ana
    Lonardi, Carolina
    Lee, Erin
    Marquez, Loreta
    Jadidi, Shirin
    Costa Filho, Octavio
    Patel, Nitin
    Geng, Dong
    Haynes, Nicole M.
    Kelly, Hannah
    Lade, Stephen
    Grimmond, Sean
    Blombery, Piers
    BLOOD, 2023, 142
  • [40] Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM)
    Theprungsirikul, Poy
    Yu, Mansen
    Rall, Kerri
    Matthews, Martin
    Neparidze, Natalia
    Parker, Terri L.
    Browning, Sabrina
    Anderson, Tara
    Stevens, Erica
    Foss, Francine M.
    Gowda, Lohith
    Pillai, Manoj
    Isufi, Iris
    Seropian, Stuart
    Mirza, Sayeef
    Bar, Noffar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345